Thomas Hayman, MD, PhD
Assistant Professor of Therapeutic RadiologyCards
About
Research
Publications
2025
P3.13.26 Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomes
Ziaks T, Park H, Oh P, Hicks D, Knowlton C, Laird J, Hayman T. P3.13.26 Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomes. Journal Of Thoracic Oncology 2025, 20: s516. DOI: 10.1016/j.jtho.2025.09.962.Peer-Reviewed Original ResearchP1.07.36 A Three-Gene Signature Predicting Local Recurrence in Stage I-III NSCLC Patients Treated With Radiation Therapy
Lee V, Oh P, Jani K, Rybkin A, Kim S, Patel A, Kang J, Park H, Hayman T. P1.07.36 A Three-Gene Signature Predicting Local Recurrence in Stage I-III NSCLC Patients Treated With Radiation Therapy. Journal Of Thoracic Oncology 2025, 20: s151. DOI: 10.1016/j.jtho.2025.09.279.Peer-Reviewed Original ResearchCardiac Toxicity Following SBRT for Centrally Located Lung Tumors: Assessing the Impact of Radiation Dose Metrics
Shen J, Oh P, Hayman T, Knowlton C, Hicks D, Laird J, Park H. Cardiac Toxicity Following SBRT for Centrally Located Lung Tumors: Assessing the Impact of Radiation Dose Metrics. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: e212. DOI: 10.1016/j.ijrobp.2025.06.3759.Peer-Reviewed Original ResearchStereotactic body radiotherapyCentrally located lung tumorsSingle-institution retrospective analysisNon-small cell lung cancerIncidence of cardiac eventsDose-volume histogramsOverall survivalCardiac eventsCoronary artery diseaseDose metricsHeart doseCardiac toxicityLung tumorsPatients treated with stereotactic body radiotherapySingle-institution retrospective analysis of patientsEarly-stage non-small cell lung cancerTreated with stereotactic body radiotherapyNew-onset atrial fibrillation/flutterRetrospective analysis of patientsDevelopment of cardiac eventsMaximum heart doseOligometastatic lung diseaseRadiation dose metricsSmall-volume dosesCentrally located tumorsRetrospective Study of the Efficacy and Safety of Lung Malignancy Radiation In-Field of Prior Ipsilateral Breast Radiation
Lawlor M, Park H, Knowlton C, Housri N, Hicks D, Laird J, Evans S, Hayman T. Retrospective Study of the Efficacy and Safety of Lung Malignancy Radiation In-Field of Prior Ipsilateral Breast Radiation. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: e179-e180. DOI: 10.1016/j.ijrobp.2025.06.3687.Peer-Reviewed Original ResearchSafety of re-irradiationWhole breast radiationBreast radiationChest wall necrosisRe-IrradiationLocal recurrenceLung malignancyDose exposureRetrospective studyBreast radiation therapyWall necrosisCourse of radiationPrimary lung cancerCumulative dose exposureEffective local controlConcurrent palbociclibLung SBRTRadiation pneumonitisRefused surgeryRadiation therapyClinical toxicityFlap reconstructionPrimary endpointSecondary endpointsSurgical candidatesThe Role of TP53 in Nodal Metastasis: A Molecular Guide for Neck Management in Oral Cavity Cancer
Lee V, Rybkin A, Oh P, Izreig S, Park H, Morris L, Hayman T, Young M, Pickering C, Mehra S, Lee N, Kang J. The Role of TP53 in Nodal Metastasis: A Molecular Guide for Neck Management in Oral Cavity Cancer. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: s196. DOI: 10.1016/j.ijrobp.2025.07.1284.Peer-Reviewed Original ResearchIndependent predictor of lymph node metastasisPredictor of lymph node metastasisSentinel lymph node biopsyOral cavity carcinomaLymph node metastasisMultivariate logistic regression modelUnivariate logistic regressionIndependent predictorsTP53 mutationsRobust independent predictorCT stagingFeasibility of sentinel lymph node biopsyIntegration of molecular biomarkersRisk of lymph node metastasisPrediction of lymph node metastasisPathologically node-positiveRadiation target volumeRadiation therapy volumeAssociated with lymph node metastasisLymph node biopsyOral cavity cancerTumor genomic alterationsLevel 1 evidencePresence of mutationsNode-positiveGenomic Predictors of Brain Metastases in Non-Small Cell Lung Cancer: Implications for Early Detection and Targeted Surveillance
Lee V, Oh P, Rybkin A, Jani K, Patel A, Hayman T, Kim S, Park H. Genomic Predictors of Brain Metastases in Non-Small Cell Lung Cancer: Implications for Early Detection and Targeted Surveillance. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: e180-e181. DOI: 10.1016/j.ijrobp.2025.06.3689.Peer-Reviewed Original ResearchNon-small cell lung cancerBrain metastasesCell lung cancerAdvanced non-small cell lung cancerLung cancerComplication of non-small cell lung cancerNon-small cell lung cancer patientsPredictors of brain metastasisAdvanced diagnosisFlatiron Health databasePersonalized surveillance strategyUS cancer clinicsGenomic predictorsClinico-genomic databaseMolecular risk factorsUnivariate logistic regressionSymptomatic BMNon-smallBrain MRIPotential molecular pathwaysRisk factorsHigh riskPatientsCancer clinicMetastasisRole of PLK4 inhibition in cancer therapy
Banik K, Hayman T. Role of PLK4 inhibition in cancer therapy. Cancer And Metastasis Reviews 2025, 44: 55. PMID: 40512236, DOI: 10.1007/s10555-025-10271-5.Peer-Reviewed Original ResearchConceptsAssociated with more advanced diseaseCancer therapyAssociated with tumor progressionMore advanced diseasePolo-like kinase 4PLK4 overexpressionMultiple cancer typesAdvanced diseaseTherapeutic resistanceClinical outcomesTumor progressionSmall molecule inhibitorsHuman tumorsCancer typesDNA-damaging agentsSerine-threonine kinaseCancerOncogenic processesTherapeutic gainTherapeutic targetPolo-like kinase 4 inhibitorPLK4 inhibitionKinase 4Genomic instabilityTherapyPLK4 Inhibition as a Strategy to Enhance Non-Small Cell Lung Cancer Radiosensitivity.
Dominguez-Vigil I, Banik K, Baro M, Contessa J, Hayman T. PLK4 Inhibition as a Strategy to Enhance Non-Small Cell Lung Cancer Radiosensitivity. Molecular Cancer Therapeutics 2025, 24: 1350-1361. PMID: 40296663, PMCID: PMC12353405, DOI: 10.1158/1535-7163.mct-24-0978.Peer-Reviewed Original ResearchNon-small cell lung cancerLung cancerCFI-400945Mitotic catastropheNon-small cell lung cancer radiosensitizationRadiosensitivity of NSCLC cell linesCentrosome amplificationRadiation-induced tumor growth delayPLK4 inhibitionCell deathCurative-intent chemoradiationIncreased G2/M cell cycle arrestPolo-like kinase 4Subtype of lung cancerCell lung cancerIncreased centrosome amplificationCancer-related mortalityG2/M cell cycle arrestNSCLC cell linesCell cycle phase distributionClinical trial evaluationTargeting PLK4NSCLC in vitroCell cycle arrestPotential therapeutic target
2024
Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Ninia J, Verma N, Laird J, Hayman T, Knowlton C, Peters G, Campbell A, Housri N, Feghali K, de Jong D, Park H. Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e51. DOI: 10.1016/j.ijrobp.2024.07.1890.Peer-Reviewed Original ResearchExtensive-stage small cell lung cancerProgression-free survivalSmall cell lung cancerOverall survivalCell lung cancerOligometastatic diseaseChemo-ImmunotherapyLung cancerSuperior progression-free survivalMedian follow-up timePatients treated with CCSites of disease involvementConsolidative thoracic radiotherapyAssociated with improved outcomesChemotherapy-based treatmentStratified Cox proportional hazard regressionsLog-rank testCox proportional hazards regressionDisease burdenTime of diagnosisKaplan-Meier estimatesProportional hazards regressionConsolidation radiotherapyPolymetastatic diseaseOligometastatic patientsRethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity
Hayman T. Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity. JNCI Cancer Spectrum 2024, 8: pkae045. PMID: 38950525, PMCID: PMC11216723, DOI: 10.1093/jncics/pkae045.Peer-Reviewed Original Research
Clinical Care
Overview
Thomas Hayman, MD, PhD, is a therapeutic radiologist who specializes in treating cancers of the lung, head and neck, skin, and more. He employs advanced radiation techniques, including stereotactic radiosurgery and intensity-modulated radiation therapy (which uses precise computer planning to target tumors), to manage various malignancies such as those in the central nervous system, prostate, and gastrointestinal tract.
As an assistant professor of therapeutic radiology at Yale School of Medicine, Dr. Hayman studies how cancer cells resist damage from radiation. He aims to discover better ways to overcome these defenses, ultimately translating new findings into clinical practice.
Dr. Hayman received his medical degree and doctoral degree from the University of South Florida Morsani College of Medicine. He completed a residency in radiation oncology at Yale New Haven Hospital.
Clinical Specialties
Fact Sheets
Merkel Cell Carcinoma (MCC)
Learn More on Yale MedicineHead and Neck Cancer
Learn More on Yale MedicineRadiofrequency Ablation (RFA)
Learn More on Yale MedicineRhabdomyosarcoma
Learn More on Yale Medicine
Yale Medicine News
News & Links
Get In Touch
Contacts
Therapeutic Radiology
Yale University PO Box 208040
New Haven, CT 06513
United States
Locations
Yale Therapeutic Radiology
Academic Office
Hunter Building
15 York Street, Ste H213E
New Haven, CT 06510
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.